biotech / news / / Devdiscourse
Danish company LEO Pharma is stepping up its dermatological game by acquiring U.S. drug developer Replay for $50 million upfront.
LEO Pharma is acquiring U.S. drug developer Replay for $50 million upfront.
KEY POINTS
- The LEO Pharma acquisition aims to enhance treatments for rare genetic skin diseases.
- Bristol Myers Squibb's quarterly revenue reached $11.49 billion, surpassing Wall Street expectations.
- Cardinal Health's shares fell 8% after third-quarter revenue missed estimates, partly due to Inflation Reduction Act regulations.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →